Antiarrhythmic therapy: New additions and future expectations

W. B. Ross, S. M. Mohiuddin

Research output: Contribution to journalArticlepeer-review


The major promise of aprindine, which is under investigation in the United States, is as an oral agent for maintenance therapy of arrhythmias. It is effective in controlling incessant ventricular tachycardia. Since tocainide does not undergo extensive 'first-pass' metabolism by the liver, it becomes an effective oral agent in treating drug-refractory ventricular arrhythmias. Side effects are mild or moderate, with CNS involvement being the most common.

Original languageEnglish (US)
Pages (from-to)30-35
Number of pages6
Issue number1
StatePublished - Jan 1 1983

All Science Journal Classification (ASJC) codes

  • Geriatrics and Gerontology


Dive into the research topics of 'Antiarrhythmic therapy: New additions and future expectations'. Together they form a unique fingerprint.

Cite this